NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Top players featured include known names such as COMPASS Pathways (NASDAQ: CMPS), Silo Pharma (NASDAQ: SILO), Numinus Wellness (OTCMKTS: NUMIF), Cybin (NYSE: CYBN), Mind Medicine (MindMed) (NASDAQ: MNMD), PharmaTher Holdings (OTCMKTS: PHRRF) and atai Life Sciences (NASDAQ: ATAI); yet also general biotech industry heavyweights like Jazz Pharmaceuticals (NASDAQ: JAZZ), Janssen Pharmaceuticals (NYSE: JNJ) and Pfizer (NYSE: PFE).

The global market’s size is predicted to grow at a CAGR of around 14% in the next 12 years, garnering a revenue of $12 billion by the end of 2035, up from 2022’s $3 billion.

See Also: Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions

Context And Key Takeaways

As most pharmaceutical market projections do, the research contemplates …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.